Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) has been assigned an average rating of “Hold” from the ten analysts that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.88.
TEVA has been the topic of a number of research analyst reports. Jefferies Financial Group cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating and upped their price target for the company from $10.00 to $12.00 in a research report on Thursday, January 19th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $13.00 to $14.00 and gave the stock an “overweight” rating in a research note on Thursday, February 9th. JPMorgan Chase & Co. downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and cut their price objective for the stock from $11.00 to $10.00 in a report on Monday, November 14th. Finally, Piper Sandler cut their price target on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, November 23rd.
Insider Buying and Selling
In other Teva Pharmaceutical Industries news, VP David Matthew Stark sold 63,383 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $626,857.87. Following the completion of the sale, the vice president now owns 2,974 shares in the company, valued at approximately $29,412.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Teva Pharmaceutical Industries news, EVP Sven Dethlefs sold 19,355 shares of the business’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $9.93, for a total transaction of $192,195.15. Following the completion of the transaction, the executive vice president now owns 223,447 shares in the company, valued at approximately $2,218,828.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP David Matthew Stark sold 63,383 shares of the business’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $9.89, for a total value of $626,857.87. Following the transaction, the vice president now owns 2,974 shares of the company’s stock, valued at approximately $29,412.86. The disclosure for this sale can be found here. Insiders sold a total of 158,884 shares of company stock valued at $1,572,797 over the last three months. 0.82% of the stock is currently owned by company insiders.
Institutional Trading of Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Price Performance
Shares of NYSE:TEVA opened at $9.12 on Friday. The business has a 50 day moving average price of $10.26 and a 200 day moving average price of $9.27. The company has a quick ratio of 0.72, a current ratio of 1.05 and a debt-to-equity ratio of 2.20. Teva Pharmaceutical Industries has a twelve month low of $6.78 and a twelve month high of $11.44. The company has a market cap of $10.13 billion, a price-to-earnings ratio of -4.30, a PEG ratio of 2.70 and a beta of 1.22.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last announced its quarterly earnings results on Wednesday, February 8th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.04. The firm had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.90 billion. Teva Pharmaceutical Industries had a positive return on equity of 28.06% and a negative net margin of 15.76%. Research analysts predict that Teva Pharmaceutical Industries will post 2.31 earnings per share for the current year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.